Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06600152 · ClinicalTrials.gov registry record · NA

Safety of Microporous Annealed Particle (MAP) Wound Matrix in Patients With Clean Surgical Wounds.

A NA study of Wound Heal, sponsored by Tempo Therapeutics.

Active
Registry status
NA
Development phase
40
Enrollment target
3
Study locations

NCT06600152 is a NA study of Wound Heal that is active but no longer recruiting, run by Tempo Therapeutics. The registered enrollment target is 40 participants, below the 118-participant average among 23 other Wound Heal trials with a reported enrollment target (66% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06600152, a NA study of Wound Heal, is active but no longer recruiting, sponsored by Tempo Therapeutics.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
40 participants
Enrollment target
3
Study locations

Study Summary

A randomized, open-label, investigational safety evaluation of the Microporous Annealed Particle (MAP) Wound Matrix (TT101) device as a volumetric biomaterial scaffold applied to clean wounds after skin cancer surgery with Mohs micrographic surgery (MMS) compared to control.

Conditions Studied

Interventions

  • DEVICE MAP Wound Matrix
  • DEVICE DuoDerm

Study Locations (3)

California

  • Cal Coast Dermatology - Encino

Indiana

  • Laser and Skin Surgery Center of Indiana - Indianapolis

Texas

  • Studies in Dermatology - Cypress

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2024-08-26
Est. Completion 2026-08-30
Phase NA

Sponsor

Tempo Therapeutics

1 total trials

What the Registry Record Tells You About NCT06600152

The ClinicalTrials.gov registry entry for NCT06600152 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 118-participant average among 23 other Wound Heal trials with a reported enrollment target (66% lower). The listed sponsor is Tempo Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Wound Heal appearing as the primary indexed condition, and to 2 interventions - of which MAP Wound Matrix is the first listed.

NCT06600152 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Indiana, Texas.

Frequently Asked Questions

What is clinical trial NCT06600152 about?

NCT06600152 is a clinical study titled "Safety of Microporous Annealed Particle (MAP) Wound Matrix in Patients With Clean Surgical Wounds.". A randomized, open-label, investigational safety evaluation of the Microporous Annealed Particle (MAP) Wound Matrix (TT101) device as a volumetric biomaterial scaffold applied to clean wounds after skin cancer surgery with Mohs micrographic surgery (MMS) compared to control.

What is the current status of trial NCT06600152?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2024-08-26. Estimated completion is 2026-08-30.

What conditions does trial NCT06600152 study?

This clinical trial studies the following conditions: Wound Heal.

What interventions are being tested in trial NCT06600152?

The interventions under investigation include: MAP Wound Matrix (DEVICE), DuoDerm (DEVICE).

Who is sponsoring clinical trial NCT06600152?

This trial is sponsored by Tempo Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06600152 being conducted?

This trial has 3 study locations across California, Indiana, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Wound Heal

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.